Acute pulmonary emboli following rebound phenomenon after Nirmatrelvir/Ritonavir treatment for COVID-19

The return of COVID-19 symptoms after Nirmatrelvir/Ritonavir (Nm/R) treatment is being increasingly reported. Limited evidence suggests most cases of rebound symptoms are mild and do not require further intervention. Here we present a male veteran reporting rebound symptoms who was found to be hypox...

Descripción completa

Detalles Bibliográficos
Autores principales: Birabaharan, Morgan, Martin, Thomas C.S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9356756/
https://www.ncbi.nlm.nih.gov/pubmed/35970690
http://dx.doi.org/10.1016/j.ajem.2022.08.012
_version_ 1784763587448799232
author Birabaharan, Morgan
Martin, Thomas C.S.
author_facet Birabaharan, Morgan
Martin, Thomas C.S.
author_sort Birabaharan, Morgan
collection PubMed
description The return of COVID-19 symptoms after Nirmatrelvir/Ritonavir (Nm/R) treatment is being increasingly reported. Limited evidence suggests most cases of rebound symptoms are mild and do not require further intervention. Here we present a male veteran reporting rebound symptoms who was found to be hypoxic with pulmonary emboli. Our case highlights the need to evaluate known complications of SARS-CoV-2 including venous thromboembolism in patients reporting recurring symptoms. Further, cases of severe rebound phenomenon should continue to be reported by clinicians to better appreciate the use of the Nm/R during the Omicron wave and among vaccinated persons.
format Online
Article
Text
id pubmed-9356756
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-93567562022-08-07 Acute pulmonary emboli following rebound phenomenon after Nirmatrelvir/Ritonavir treatment for COVID-19 Birabaharan, Morgan Martin, Thomas C.S. Am J Emerg Med Article The return of COVID-19 symptoms after Nirmatrelvir/Ritonavir (Nm/R) treatment is being increasingly reported. Limited evidence suggests most cases of rebound symptoms are mild and do not require further intervention. Here we present a male veteran reporting rebound symptoms who was found to be hypoxic with pulmonary emboli. Our case highlights the need to evaluate known complications of SARS-CoV-2 including venous thromboembolism in patients reporting recurring symptoms. Further, cases of severe rebound phenomenon should continue to be reported by clinicians to better appreciate the use of the Nm/R during the Omicron wave and among vaccinated persons. Elsevier Inc. 2022-11 2022-08-06 /pmc/articles/PMC9356756/ /pubmed/35970690 http://dx.doi.org/10.1016/j.ajem.2022.08.012 Text en © 2022 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Birabaharan, Morgan
Martin, Thomas C.S.
Acute pulmonary emboli following rebound phenomenon after Nirmatrelvir/Ritonavir treatment for COVID-19
title Acute pulmonary emboli following rebound phenomenon after Nirmatrelvir/Ritonavir treatment for COVID-19
title_full Acute pulmonary emboli following rebound phenomenon after Nirmatrelvir/Ritonavir treatment for COVID-19
title_fullStr Acute pulmonary emboli following rebound phenomenon after Nirmatrelvir/Ritonavir treatment for COVID-19
title_full_unstemmed Acute pulmonary emboli following rebound phenomenon after Nirmatrelvir/Ritonavir treatment for COVID-19
title_short Acute pulmonary emboli following rebound phenomenon after Nirmatrelvir/Ritonavir treatment for COVID-19
title_sort acute pulmonary emboli following rebound phenomenon after nirmatrelvir/ritonavir treatment for covid-19
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9356756/
https://www.ncbi.nlm.nih.gov/pubmed/35970690
http://dx.doi.org/10.1016/j.ajem.2022.08.012
work_keys_str_mv AT birabaharanmorgan acutepulmonaryembolifollowingreboundphenomenonafternirmatrelvirritonavirtreatmentforcovid19
AT martinthomascs acutepulmonaryembolifollowingreboundphenomenonafternirmatrelvirritonavirtreatmentforcovid19

Ejemplares similares